Skip to main content
Premium Trial:

Request an Annual Quote

NIH s Chem Genomics Center to Use Invitrogen Tools in Screening Program

NEW YORK, March 7 (GenomeWeb News) - The National Institutes of Health's ChemicalGenomicsCenter will use Invitrogen's CellSensor cell lines and GeneBLAzer beta-lactamase reporter gene technology to identify compounds that modulate disease-relevant signaling pathways, the company said today.


The NCGC will use the assay technology with quantitative high-throughput screening program, Invitrogen said, and all of the screening data from the collaboration will be deposited in PubChem.


As these new assays generate compounds of interest, Invitrogen and the NCGC may agree to work together to identify the protein targets they affect through the use of additional Invitrogen technologies such as Stealth RNAi and Protoarray Human Protein Microarrays, Invitrogen said.